



(51) International Patent Classification:

A61K 31/395 (2006.01) *A61K 31/13* (2006.01)
A61K 31/4965 (2006.01) *A61K 31/33* (2006.01)

(21) International Application Number:

PCT/US2024/058371

(22) International Filing Date:

04 December 2024 (04.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/606,375 05 December 2023 (05.12.2023) US

(71) Applicant: **VALO HEALTH, INC.** [US/US]; 399 Boylston Street, Suite 505, Boston, Massachusetts 02116 (US).

(72) Inventors: **GORDON, William**; c/o Valo Health, Inc., 399 Boylston St., Suite 505, Boston, Massachusetts 02116 (US). **XU, Jinwang**; c/o Valo Health, Inc., 399 Boylston St., Suite 505, Boston, Massachusetts 02116 (US). **EVARISTI, Maria Francesca**; c/o Sanofi, 46 Avenue de

la Grande Armée, 75017 Paris (FR). **POIRIER, Bruno**; c/o Sanofi, 46 Avenue de la Grande Armée, 75017 Paris (FR). **SLOWINSKI, Franck**; c/o Sanofi, 46 Avenue de la Grande Armée, 75017 Paris (FR). **MALANDA, André**; c/o Sanofi, 46 Avenue de la Grande Armée, 75017 Paris (FR). **GILLE-FANET, Catherine**; c/o Sanofi, 46 Avenue de la Grande Armée, 75017 Paris (FR). **ALMARIO, Antonio**; c/o Sanofi, 46 Avenue de la Grande Armée, 75017 Paris (FR). **BRAUN, Alain**; c/o Sanofi, 46 Avenue de la Grande Armée, 75017 Paris (FR). **ABOUABDELLAH, Ahmed**; c/o Sanofi, 46 Avenue de la Grande Armée, 75017 Paris (FR). **NICOLAI, Eric**; c/o Sanofi, 46 Avenue de la Grande Armée, 75017 PARIS (FR). **CRESPIN, Olivier**; c/o Sanofi, 46 Avenue de la Grande Armée, 75017 Paris (FR). **BISCAR-RAT, Sandrine**; c/o Sanofi, 46 Avenue de la Grande Armée, 75017 Paris (FR). **GROB, Jonathan**; c/o Valo Health, Inc., 399 Boylston St., Suite 505, Boston, Massachusetts 02116 (US). **MONOS, Tim**; c/o Valo Health, Inc., 399 Boylston St., Suite 505, Boston, Massachusetts 02116 (US). **STANGELAND, Eric Lars**; c/o Valo Health, Inc., 399 Boylston St., Suite 505, Boston, Massachusetts 02116 (US).



(54) Title: S1P₁ RECEPTOR AGONISTS AND USES THEREOF

FIG. 40



(57) Abstract: The present invention relates to compounds of formula (1a): (1a) or enantiomers, racemates, or pharmaceutically acceptable salts thereof. The present invention further relates to pharmaceutical compositions comprising compounds of formula (1a) or enantiomers, racemates, or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients and to methods of treating autoimmune diseases, diseases of the central nervous system, and white blood cell disorders comprising administering to an individual in need thereof a pharmaceutical composition of the invention.

[Continued on next page]

(74) **Agent:** SUSSMAN, Adam et al.; Crowell & Moring LLP,
1001 Pennsylvania Ave., NW, Fl. 10, Washington, District
of Columbia 20004 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))